The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new ...

Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday as strong demand for its cough-and-cold ...

Kenvue Inc. has announced the appointment of Amit Banati as chief financial officer, effective today. He will be responsible ...

Shares of Kenvue Inc. KVUE slid 1.80% to $24.00 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 3.26% to 5,844.19 and the ...

Shares of Kenvue rose in early Thursday trading after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter ...

The leadership change comes at the end of a week in which the California-based toymaker landed squarely in the crosshairs of ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

The Neutrogena and Aveeno owner has also increased its 2025 full-year outlook to reflect the impact of costs associated with ...

Kenvue Inc. maintained its sales expectations for the year while lowering its profitability target as tariffs raise costs.

Kenvue Inc. reported second-quarter earnings that surpassed analyst estimates, while updating its full-year 2025 guidance to account for tariffs and currency headwinds.

Kenvue named Kellanova Chief Financial Officer Amit Banati to that role at the over-the-counter drug maker, replacing current financial chief Paul Ruh, effective May 12. Banati has worked in executive ...

Kenvue KVUE1.58%increase; green up pointing triangle, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial ...